Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Skrit37on Apr 05, 2021 5:56pm
144 Views
Post# 32939008

RE:Never seen such a loss

RE:Never seen such a loss
Deadornot wrote: due to EMOTIONS. If you look at the facts, we should be going up. 

We're buying a company that brings in roughly $12 million per year (according to a link Jony linked the other day). Q1 we started testing travellers for COVID-19 for flights going to China, Barbados, and other (I think Q1 alone will be north of $4 million). Q4 was good. With this company we are buying, we are USING ARISTOTLE. $1,500 per test x 3000 people is $4.5 million alone just with this AVRT program. This does not include the multiple tests that the Chief Medical Officer of Care Oncology said they would do. So double that $4.5 million. 

I understand the frustration.... I AM FRUSTRATED that we didn't shoot up to $5 along with a halt. But guys, think of where we'll be in 6 months.


Your assuming all 3000 patients are female then? Do you know this for a fact?
<< Previous
Bullboard Posts
Next >>